+Vote!
Market Wire - Medical and Healthcare: Medical Devices (Free subscription) | 04/09/2008
LOS ANGELES, CALIFORNIA, USA and MONTREAL, QUEBEC, CANADA (MARKET WIRE) Abraxis BioScience, Inc. (NASDAQ: ABII) and ProMetic Life Sciences Inc. (TSX: PLI) announced today that they have signed definitive agreements for the development and commercialization, on a world-wide basis (excluding China and Taiwan), of four biopharmaceutical products targeting underserved medical conditions. These represent...
+Vote!
Business Wire (Free subscription) | 04/09/2008
LOS ANGELES & MONTREAL--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII) and ProMetic Life Sciences Inc. (TSX:PLI) announced today that they have signed definitive agreements
+Vote!
Business Wire (Free subscription) | 13/08/2008
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the second quarter ended June
+Vote!
Business Wire (Free subscription) | 06/08/2008
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biopharmaceutical company, today announced it will release its 2008 second quarter financial
+Vote!
India Press Release (Free subscription) | 22/07/2008
/India PRwire/ - Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within...
+Vote!
BrandFaqs: The Brand Blog (Free subscription) | 19/07/2008
Biotechnology major Biocon Ltd will market Abraxane drug of the US-based Abraxis BioScience in India for treating breast cancer, a top company official said here Friday. To be priced at about $400 (Rs.17,200) per 100mg vial in India, the drug will be cheaper by 60 percent than in the US where it is sold at $1,000 (Rs.43,000) per vial of same measure. Abraxane will be the second oncotherapeutics drug...
+Vote!
Red Orbit (Free subscription) | 18/07/2008
Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
+Vote!
Business Wire (Free subscription) | 18/07/2008
BANGALORE, India, & LOS ANGELES--(BUSINESS WIRE)--Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology
+Vote!
Medical News Today (Free subscription) | 16/07/2008
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced it has received approval from the China State Food and Drug Administration to market ABRAXANE® Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.
+Vote!
Seeking Alpha (Free subscription) | 16/07/2008
ChinaBio Today submits: Abraxis BioScience, Inc. (ABII) received SFDA approval for ABRAXANE Paclitaxel for Injection (Albumin Bound) as a breast cancer treatment. The indication was limited to use following failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The approval was based on trials conducted in the US and in China. Currently, Abraxis...
+Vote!
Red Orbit (Free subscription) | 14/07/2008
Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.
+Vote!
Business Wire (Free subscription) | 14/07/2008
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced it has received approval from the China State Food and Drug
1Vote!
Fiercebiotech (Free subscription) | 16/06/2008
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Abraxane was approved by the FDA three years ago. This fight is far from finished, as Abraxis says it plans to appeal the ruling. - read the report from RTT News ALSO: Investors are anxiously awaiting a Phase...
+Vote!
Business Wire (Free subscription) | 13/06/2008
LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that it intends to appeal the jury ruling in the U.S.
